
SynThera Partners with Mayo Clinic for Multi-Site Clinical Trial
Landmark partnership will validate AI-powered diagnostic accuracy across 50,000 patient encounters in cardiology and oncology.
Latest updates, announcements, and insights from the world of healthcare AI
The FDA has granted SynThera breakthrough device designation for our multimodal AI system, recognizing its potential to significantly improve patient outcomes across multiple specialties.
Landmark partnership will validate AI-powered diagnostic accuracy across 50,000 patient encounters in cardiology and oncology.
Latest user analytics show significant improvements in clinical efficiency, with average documentation time reduced from 45 to 27 minutes per patient.
Funding will accelerate expansion into international markets and development of specialty-specific AI models for pediatrics and geriatrics.
Peer-reviewed study demonstrates 94.7% diagnostic accuracy across 12 medical specialties, outperforming traditional methods.
Recognition highlights our commitment to clinical-grade AI and meaningful impact on patient care across diverse healthcare settings.
Native Epic integration allows healthcare systems to deploy SynThera AI without workflow disruption, now available in Epic App Orchard.
Download our complete media kit including high-resolution logos, product screenshots, executive headshots, and company fact sheets.
2.4 MB • PNG, SVG
15.2 MB • JPG
8.7 MB • PNG
1.2 MB • PDF
For press releases, interview requests, and media partnerships
Sarah Mitchell
Director of Communications
press@synthera.health
+1 (555) 123-4567
For industry analysts and research partnerships
Dr. Michael Chen
VP of Strategy
analysts@synthera.health
+1 (555) 123-4568
Subscribe to our newsletter for the latest product updates, research insights, and industry announcements delivered directly to your inbox.
No spam, unsubscribe at any time. Read our privacy policy.
Dec 12, 2024
Dec 8, 2024
Dec 5, 2024
Dec 1, 2024